Moscow, 15 October 2010 – JSC Pharmstandard (LSE: PHST LI, RTS: PHST RU) will be announcing its 9M 2010 sales results on Thursday, 28 October 2010 at 10:00 AM Moscow time.

Pharmstandard is pleased to invite the investment community to a results conference call with the management of the company followed by a Q&A session.

Thursday, October 28, 2010
09:00 New York
14:00 London
17:00 Moscow

International Call-in Number:  +44 (0)20 7162 0025

US Call-in Number: +1 334 323 6201

Conference ID: 878312

Conference call participants can register in advance using the link below:

https://eventreg1.conferencing.com/webportal3/reg.html?Acc=916302&Conf=175079

We recommend that participants start dialling in 5-10 minutes prior to ensure a timely start to the conference call.

Pharmstandard will be represented by:
Igor Krylov, CEO
Elena Arkhangelskaya, CFO

Conference call presentation will be available on Thursday, 28 October 2010 on Company’s web-site: http://www.pharmstd.ru/investors_en/investor/p2/

The conference call replay will be available through October 31, 2010
International Replay Number: +44 (0) 20 7031 4064
US Replay Number: +1 954 334 0342
Replay Access Code: 878312

Contacts:

ILYA Krylov
IR manager
OJSC Pharmstandard
Tel: +7 495 970 0030 ext 2416
E-mail: ir@pharmstd.ru
www.pharmstd.com

                                                                                         Pharmstandard is the leader of Russian pharmaceutical industry in R&D and production of the medicinal products. 

Pharmstandard became №1 among all pharmaceutical companies represented on commercial market in Russia. Market share of Pharmstandard reached 4, 99% in the first half of 2010¹. The Company is the leader measured by sales in the whole Russian pharmaceutical market in the year 2009². Since 2007 Pharmstandard keeps its leading position in commercial segment and remains strong leader among the domestic pharmaceutical company-manufacturers, having increased it’s market share from 18,9% in 2008 up to 20% in 2009². During the tenth anniversary of «Platinum Ounce 2009», the open competition among professionals of pharma business, Pharmstandard was awarded in the nominations for «The Company of the Year - the Russian pharmaceutical products manufacturer» and «The Company of Decade - the Russian pharmaceutical products manufacturer».

Pharmstandard operates three modern pharmaceutical manufacturing facilities: JSC “Pharmstandard-Leksredstva” in Kursk, JSC “Pharmstandard-UfaVITA” in Ufa, JSC “Pharmstandard-Tomskhimpharm“  in Tomsk and medical equipment factory JSC “TZMOI” in Tyumen.

The Company has invested approximately RUR 3 billion RUR in modernization and development of production capacities reaching more than 1,35 bln units per year. All the production facilities fully comply with Russian manufacturing standards. Six production lines of JSC «Pharmstandard-Leksredstva» meet EU GMP requirements.

Pharmstandard portfolio includes over 250 products used in the treatment of diabetes, growth hormone deficiency, cardiovascular diseases, gastroenterological and neurological disorders, infectious diseases, cancer, etc. 86 products offered by Pharmstandard are included in the List of Vital and Essential Pharmaceuticals.

Among our market-leading brands are Arbidol®, Complivit®, Pentalgin®, Flucostat®, Phosphogliv®, Amixin® and Afobazol®. Antiviral product «Arbidol» was awarded for «Platinum ounce 2009» in the nominations «OTC Product of the Year» and «OTC Product of Decade». Pentalgin® has been granted “BRAND #1 IN RUSSIA” award for 2009 in analgesics category.

In 2004–1H2010, we developed and introduced over 40 new pharmaceutical products in close collaboration with the leading scientific centers of Russia.  Pharmstandard is the partner of the joint venture biotechnological project “Generium” in order to develop and manufacture innovative biological products within the state program of import substitution.

Pharmstandard holds 11,3% of shares of the company Grindeks AS, Latvia and keeps strategic partnership on distribution and promotion of Mildronate®.

Pharmstandard became a public company in 2007 by offering to the public 27.6% of its share capital in the form of GDR on the London Stock Exchange (LSE) and 18.1% of its share capital in the form of ordinary shares on two local stock exchanges (RTS, MICEX). Approximately 54.3%of voting shares of OJSC “Pharmstandard” are held by “Augment Investments Limited”.            

¹Source: “Pharmexpert” Market Research Centre (MRC) analytical research INPHARMACIA 7-8 (83)2010
²Pharmexpert (CMR) 2009 market data